Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Complement-mediated Kidney Disease”

13 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 13 results

Not applicableNot Yet RecruitingNCT07331259
What this trial is testing

CHART-C3G/CLNP023B12011

Who this might be right for
C3 GlomerulopathyComplement-mediated Kidney DiseaseProteinuria
Novartis Pharmaceuticals 83
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05517980
What this trial is testing

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

Who this might be right for
Glomerulonephritis
Kira Pharmacenticals (US), LLC. 52
Testing effectiveness (Phase 2)Study completedNCT03124368
What this trial is testing

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

Who this might be right for
C3 GlomerulonephritisDense Deposit DiseaseC3 Glomerulopathy+2 more
Alexion Pharmaceuticals, Inc. 6
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06786338
What this trial is testing

SGB-9768 in Patients with Complement-mediated Kidney Diseases

Who this might be right for
IgA Nephropathy (IgAN)C3 GlomerulopathyIC-MPGN
Suzhou Sanegene Bio Inc. 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT06209177
What this trial is testing

Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease

Who this might be right for
IgA Nephropathy
Arrowhead Pharmaceuticals 66
Testing effectiveness (Phase 2)Study completedNCT03369236
What this trial is testing

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

Who this might be right for
C3 GlomerulopathyC3 GlomerulonephritisDense Deposit Disease
Alexion Pharmaceuticals, Inc. 13
Early research (Phase 1)Study completedNCT02502903
What this trial is testing

Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders

Who this might be right for
Bullous Pemphigoid (BP)Cold Agglutinin Disease (CAD)Warm Autoimmune Hemolytic Anemia (WAIHA)+1 more
Bioverativ, a Sanofi company 122
Testing effectiveness (Phase 2)Ended earlyNCT03459443
What this trial is testing

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

Who this might be right for
C3 GlomerulonephritisC3 GlomerulopathyImmune Complex Membranoproliferative Glomerulonephritis+2 more
Alexion Pharmaceuticals, Inc. 22
Not applicableActive Not RecruitingNCT05985122
What this trial is testing

New Analytic Tools for aHUS and C3G Diagnosis

Who this might be right for
Hemolytic-Uremic SyndromeMembranoproliferative GlomerulonephritisHealthy
Mario Negri Institute for Pharmacological Research 180
Testing effectiveness (Phase 2)Looking for participantsNCT06989359
What this trial is testing

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

Who this might be right for
IgANC3GComplement-mediated Kidney Disease+2 more
ADARx Pharmaceuticals, Inc. 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07363265
What this trial is testing

Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease

Who this might be right for
Complement-mediated Renal Diseases
Longbio Pharma 46
Testing effectiveness (Phase 2)Study completedNCT05083364
What this trial is testing

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

Who this might be right for
C3 GlomerulopathyIgA Nephropathy
Arrowhead Pharmaceuticals 62
Early research (Phase 1)Study completedNCT03316521
What this trial is testing

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

Who this might be right for
Complement Mediated Diseases
Amyndas Pharmaceuticals S.A. 50